BioSensics Receives Grant Funding from the NIH in Pursuit of Important Goal

BioSensics, a leader in developing wearable sensor technologies for clinical research and medical applications, has received grant funding from the National Institutes of Health (NIH) to develop HDWear, a novel telecare solution for Huntington’s disease.

“HDWear, powered by BioSensics’ PAMSys sensor technology, will enable continuous remote monitoring of Huntington’s disease motor symptoms,” this morning’s official announcement reads.

If you’re not famialir, Huntington’s disease (HD) is a hereditary neurological disease that causes progressive nerve degeneration in the brain and affects approximately 30,000 individuals in the United States.

HD is characterized by multifaceted symptomatology including motor, cognitive, and psychiatric symptoms, which begin insidiously and progress over many years.

The 2-year project builds on pilot work performed in collaboration with the University of Rochester Medical Center and Teva Pharmaceuticals and published in the Journal of Huntington’s Disease (2016, Vol. 5, pp. 199-206). The study demonstrated a novel wearable sensor solution for remotely monitoring the severity of upper extremity chorea in Huntington’s disease.

“HD patients often have to travel long distances to be seen by knowledgeable HD clinicians. Travel is often very difficult both physically and financially for HD patients and their caregivers,” explained Dr. George Yohrling, Senior Director of Mission and Scientific Affairs of the Huntington’s Disease Society of America. “The development and eventual integration of wearable biosensors into a HD clinic would allow for remote monitoring of a patient’s motor symptoms and could alleviate this unnecessary burden on the entire HD family.”

HDWear will relieve such a burden by providing real-time, remote access to quantitative motor symptom scores previously only possible through in-clinic assessments like the Unified Huntington’s Disease Rating Scale.

To learn more about BioSensics, click here.

This post was written by:

- who has written 2086 posts on mHealthWatch.


Contact the author

0 comments
Advert